Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Baricitinib in Moderate and Severe COVID-19
NCT05056558Phase 3Unknown
- Sponsor
- Incepta Pharmaceuticals Ltd.
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in coronavirus disease 2019 (COVID-19), sponsored by Incepta Pharmaceuticals Ltd.. Status: unknown.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05056558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056558.